THE 60-SECOND GUIDE
Leuprolide
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained

What is it?
Leuprolide is a synthetic GnRH analog that initially stimulates, then suppresses, reproductive hormone signaling with continued treatment. Different products have specific indications in hormone-responsive conditions; this is deliberate hormone suppression rather than a general hormone-balancing treatment. [1]
Potential benefits
Suppresses gonadal hormone production after an initial stimulation phase. Used in several precisely defined hormone-responsive conditions. [1]
Evidence & its limits
Initial stimulation can temporarily worsen symptoms. Sustained suppression can reduce bone mineral density, some of which may not recover after stopping treatment; indication-specific duration limits and contraindications apply. Different depot preparations must not be assumed equivalent. [1]
Risks & unknowns
Can affect bone, mood, metabolism, and cardiovascular risk. The initial hormone flare can matter clinically. [1]
Status & scope
Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA Drugs@FDA database
- MedlinePlus: medication-specific uses and precautions
- LUPRON DEPOT prescribing information
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.